Compare SPB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | IOVA |
|---|---|---|
| Founded | 1906 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | 2008 |
| Metric | SPB | IOVA |
|---|---|---|
| Price | $88.68 | $5.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $82.40 | $9.00 |
| AVG Volume (30 Days) | 309.0K | ★ 16.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $2.03 | $47.74 |
| Revenue Next Year | $1.85 | $40.31 |
| P/E Ratio | $40.48 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $1.76 |
| 52 Week High | $90.60 | $5.64 |
| Indicator | SPB | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 58.76 |
| Support Level | $80.58 | $3.77 |
| Resistance Level | $90.60 | $5.63 |
| Average True Range (ATR) | 2.59 | 0.40 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 70.80 | 64.45 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.